AgingResearch.NewsJoin free

Lnp-loxl2@gel

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

Outcomes

2

ecm degradation

downin rats1

1 study

  1. Lnp-loxl2@gel inhibits ecm degradation in rats.

    “inhibited ECM catabolism by decreasing the expression of ROS in the microenvironment, thus partially restoring the physiological function of the intervertebral disc.”

    Animalsin rat IDD modelintervertebral disc

    ROS-degradable hydrogel delivering LOXL2-LNPs rescues disc degeneration by synchronously suppressing cellular senescence and oxidative damage

    Journal of nanobiotechnology10 Oct 2025

Cellular senescence

downin rats1

1 study

  1. Lnp-loxl2@gel decreases cellular senescence in rats.

    “In the rat IDD model, LNP-LOXL2@Gel not only reduced nucleus pulposus senescence, but also inhibited ECM catabolism”

    Animalsin rat IDD modelintervertebral disc

    ROS-degradable hydrogel delivering LOXL2-LNPs rescues disc degeneration by synchronously suppressing cellular senescence and oxidative damage

    Journal of nanobiotechnology10 Oct 2025

More on Cellular senescence

Latest

Related